Compound News and Research

RSS

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus Pharmaceuticals, a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome.

16 Feb 2011

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

An analysis of data including more than 500,000 adults indicates that levels in the blood of bilirubin in the normal range but relatively higher were associated with a reduced risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, according to a study in the February 16 issue of JAMA.

15 Feb 2011

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

15 Feb 2011

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

13 Feb 2011

Study sheds new light on riboswitch that turns genes on or off in response to cell's energy needs

Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.

13 Feb 2011

Rare heart defect reproduced in petri dish, hope for cure

U.S. researchers have created beating heart cells in the lab with the same heart defect using skin cells taken from children with a rare heart defect. This means they can now test new drugs in human cells instead of mice.

13 Feb 2011

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

11 Feb 2011

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.

10 Feb 2011

Scientists generate beating heart cells from skin cells of young patients with severe genetic heart defect

Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.

10 Feb 2011

Study: New curcumin-hybrid compound may help protect, regenerate brain cells after stroke

Whether or not you're fond of Indian, Southeast Asian and Middle Eastern food, stroke researchers at Cedars-Sinai Medical Center think you may become a fan of one of their key spices.

10 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis

R-Tech Ueno is pleased to announce the initiation of a Phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.

9 Feb 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Ansaris announced today that it has received a milestone payment for the successful identification of a kinase-related compound under its drug discovery collaboration with Ono Pharmaceutical Co., Ltd. Ono will initiate the preclinical study of the identified compound. This collaboration between Ansaris and Ono was established to focus on the discovery of kinase-related compounds for the treatment of cancer, inflammatory and autoimmune diseases.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Compound News and Research

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

Scientists suggest combinational therapy can improve treatment of solid tumors

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Study sheds new light on riboswitch that turns genes on or off in response to cell's energy needs

Rare heart defect reproduced in petri dish, hope for cure

RF-induced heat therapy could help treat common parasitic skin infection

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Scientists generate beating heart cells from skin cells of young patients with severe genetic heart defect

Study: New curcumin-hybrid compound may help protect, regenerate brain cells after stroke

Clinical Data reports $2.0 million revenue for third quarter 2011

Repligen third quarter total revenue increases 26% to $7,068,000

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis

NMS Labs launches unique test for Methotrexate

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News